CN Patent

CN113288887A — 用于治疗癌症的方法

Assigned to Radius Pharmaceuticals Inc · Expires 2021-08-24 · 5y expired

What this patent protects

本发明涉及癌症领域，公开了用于治疗癌症的方法，具体涉及RAD1901或其盐或其溶剂化物在制备治疗具有突变型雌激素受体α阳性癌症的受试者肿瘤的药物中的应用，RAD1901或其盐或其溶剂化物具有以下结构。所述RAD1901能够抑制ERα阳性肿瘤生长和/或引起肿瘤消退，且相比于其他内分泌疗法的副作用更小。

USPTO Abstract

本发明涉及癌症领域，公开了用于治疗癌症的方法，具体涉及RAD1901或其盐或其溶剂化物在制备治疗具有突变型雌激素受体α阳性癌症的受试者肿瘤的药物中的应用，RAD1901或其盐或其溶剂化物具有以下结构。所述RAD1901能够抑制ERα阳性肿瘤生长和/或引起肿瘤消退，且相比于其他内分泌疗法的副作用更小。

Drugs covered by this patent

Patent Metadata

Patent number
CN113288887A
Jurisdiction
CN
Classification
—
Expires
2021-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Radius Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.